Human-derived fecal microbiota transplantation alleviates mitochondrial dysfunction and social deficits in the BTBR mouse model for autism

<p><span><span>Autism spectrum disorder (ASD) is a heterogeneous neurodevelopmental condition characterized by social communication deficiencies and stereotypic behaviors influenced by hereditary and/or environmental risk factors. There are currently no approved medications for treating the core symptoms of ASD. Human fecal microbiota transplantation (FMT) has emerged as a potential intervention to improve autistic symptoms, but the underlying mechanisms are not fully understood.&nbsp;</span></span><span><span><span><span>In this study, we evaluated the effects of human-derived FMT on behavioral and multi-omics profiles of the BTBR mice, an established model for ASD. FMT effectively alleviated the social deficits in the BTBR mice and normalized their distinct plasma metabolic profile, notably reducing the elevated long-chain acylcarnitines. Integrative analysis linked these phenotypic changes to specific&nbsp;<em>Bacteroides</em> species and vitamin B₆ metabolism. Indeed, vitamin B₆ supplementation improved the social behaviors in BTBR mice. Collectively, these findings shed new light on the interplay between FMT and vitamin B₆ metabolism and revealed a potential mechanism underlying the therapeutic role of FMT in ASD.</span></span></span></span></p>